CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.
Real-time market intelligence across asset classes
Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.
| Insider | Role | Date | Type | Value |
|---|---|---|---|---|
| Muniz Quintanilla Daniel | Director | Feb 06 '26 | Buy | 200882.0 |
| Whittaker Dawn Patricia | Director | Feb 04 '26 | Buy | 37440.0 |
| Dorward-King Elaine J | Director | Jan 27 '26 | Option Exercise | 350592.0 |
| Dorward-King Elaine J | Director | Jan 27 '26 | Sale | 115.0 |
Source: FinViz — Data may be delayed
AI-curated news influencing NG price, sentiment, and trend
This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.
Shares of Jensen Huang’s company have struggled to make headway since its previous results day.
Hang Seng Indexes Co. is adding Hua Hong Grace Semiconductor Ltd. and Weichai Power Co. to Hong Kong’s equity benchmark, …
(Click here or type SQUA <GO> to listen to Bloomberg’s new EMEA Equities Squawk)
An ABC on ABCPs
Both of these entertainment giants have lost money for their shareholders in 2026.
Multi-Provider AI Analysis